Vedolizumab Induction May Prevent Celiac Enteritis

Inclusion Criteria: * Patients must meet the following criteria for study entry: * Adult patients with Celiac Disease (CD) * Without any additional co-morbidities * Normal renal and hepatic function * Diagnosis of CD established at least 6 months prior to trial with diagnostic serology, genetic profile, endoscopic appearance and histopathology report In histologic and serologic remission (defined as MARSH 0 and negative anti-tissue transglutaminase, etc.) following a gluten free diet * Naïve to treatment with vedolizumab * Able and willing to provide written informed consent * Eligibility criteria for laboratory profiles - healthy patient normal laboratory reference values * WBC 4.5-12.0 k/UL * Platelet count- 140-415 k/UL * Hemoglobin- 11.0-17.4 %g/dL * Renal Function- * Creatinine- 0.5-1.3 mg/dL * BUN- 5-20 mg/dL * Hepatic Function * Albumin - 3.3-5.0 g/dL * INR- 0.9-1.1 * AST- 0-37 U/L * ALT- 0-40 U/L * Total Bilirubin- 0.1-1.3 mg/dL * Alk Phos- 35-150 U/L Exclusion Criteria: * Patients who meet any of the following criteria will be excluded from study entry: * Abnormal MARSH score on enrollment histopathology * Elevated celiac serologies (anti-tissue transglutaminase, etc.) * Current use of biologics or immunomodulators Adalimumab, infliximab, Ustekinumab, Golimumab, Tocilizumab, Certolizumab, Etanercept, Rituximab, Anakinra, Abatacept, Tofacitinib, Methotrexate, Azathioprine, 6-MP. * Current use of immunosuppressive therapy including intermittent systemic corticosteroids within two months of vedolizumab induction * History of intestinal lymphoma (MALToma, etc.) * History of cancer including hematologic malignancy, solid tumors, carcinoma in situ, etc. * Pregnant or lactating * Fertile females will require at least one form of birth control * Lack of peripheral venous access * Inability to comply with study protocol, in the opinion of the investigator * Neurological conditions which may interfere with monitoring for PML * History of demyelinating disease or history of major neurological disease * History of alcohol, drug or chemical abuse \< 6 months prior to screening * History of active tuberculosis (TB) or a positive screening test for latent mycobacterium tuberculosis infection * Positive PPD= \> 10 mm or \> 5mm in patients on 15 mg or more of prednisone * History of BCG vaccination should be screened using Quantiferon TB Gold test * An Indeterminate Quantiferon test will require a chest X-ray to rule out active TB and consultation with an infectious disease specialist to confirm the risk of latent * TB is low and that patients can be safely enrolled in the trial * History of recurrent opportunistic infections and/or of severe or disseminated viral infections * Active autoimmune disease * Active inflammatory bowel disease